Sanofi picks up Kadmon and its transplant drug in $1.9B buyout, giving Sam Waksal 2 Big Pharma buyouts under his belt
It’s not just hot spaces that Paul Hudson wants Sanofi to lead in.
The CEO’s latest, $1.9 billion M&A gamble points straight to Kadmon $KDMN and its newly approved drug, Rezurock, which is billed as a first-in-class treatment for chronic graft-versus-host disease — and a strong addition to Sanofi’s transplant portfolio.
For Kadmon, the buyout marks a sweet reward at the end of an uphill journey that spanned more than a decade and vindication for a notorious name in biotech, even if the ultimate price is actually lower than its IPO price five years ago.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.